Zacks Investment Research upgraded shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has $1.50 price objective on the biotechnology company’s stock.
According to Zacks, “Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). “
Several other analysts have also issued reports on the company. BidaskClub lowered Nabriva Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, December 24th. Wedbush reaffirmed an outperform rating and issued a $7.00 target price on shares of Nabriva Therapeutics in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a buy rating on shares of Nabriva Therapeutics in a research note on Wednesday, November 13th. Finally, ValuEngine raised Nabriva Therapeutics from a hold rating to a buy rating in a research note on Saturday, January 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $6.64.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. The business had revenue of $6.92 million during the quarter, compared to analyst estimates of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%. On average, equities analysts anticipate that Nabriva Therapeutics will post -1.14 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Nabriva Therapeutics in the third quarter valued at approximately $40,000. Sterling Investment Advisors Ltd. lifted its position in Nabriva Therapeutics by 100.0% in the third quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 10,000 shares during the last quarter. State Street Corp bought a new stake in Nabriva Therapeutics in the third quarter valued at approximately $65,000. Tower Research Capital LLC TRC lifted its position in Nabriva Therapeutics by 1,616.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 35,771 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 33,687 shares during the last quarter. Finally, Raymond James & Associates bought a new stake in Nabriva Therapeutics in the fourth quarter valued at approximately $52,000. Hedge funds and other institutional investors own 2.76% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Recommended Story: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.